ZETA-1 Phase 2 Trial Safety and Tolerability Results for of APX3330: A Novel, Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy
APX3330
Presented at Women in Ophthalmology 2023
Filter by:
Presented at Women in Ophthalmology 2023
Presented at American Society of Retina Specialists 2023
Presented at American Society of Retina Specialists 2023
Presented at American Society of Cataract and Refractive Surgery 2023
Presented at American Society of Cataract and Refractive Surgery 2023
Presented at American Society of Cataract and Refractive Surgery 2023
Presented at American Society of Cataract and Refractive Surgery 2023
Presented at American Society of Cataract and Refractive Surgery 2023
Presented at American Society of Cataract and Refractive Surgery 2023